Regenerative medicine company StimLabs has announced the availability of Corplex P, a medical device for wound care, in the US.

Corplex P is claimed to be the first and only device derived from the human umbilical cord extracellular matrix (ECM).

It is specifically designed to aid in the healing of challenging wounds. Its unique composition, which includes key connective tissue matrix components such as collagens and glycosaminoglycans, provides a moist environment conducive to wound healing.

The device's processing technique preserves these vital components.

The ability of Corplex P to regulate moisture exchange is one of its primary benefits. Its hydrophilic nature, particularly due to the presence of hyaluronic acid, contributes to its absorptive properties.

Its particulate format not only allows for efficient moisture management but also ensures that the device conforms to the wound bed, promoting better integration into the healing tissue.

Corplex P can be used for a wide variety of wounds, including pressure ulcers, diabetic ulcers, and surgical wounds. Its optimised design for complex wound beds, natural resorption into the wound, and facilitation of a moist wound environment underscore its key advantages.

StimLabs founder and CEO John Daniel said: “Chronic and acute wounds present a significant healthcare challenge, affecting millions of individuals each year.

“With Corplex P, StimLabs aims to address this challenge by providing clinicians and patients with an advanced solution for wound management.

“Corplex P offers an opportunity for a better quality of life for those in need of care and since its limited release, healthcare practitioners have shown excitement for the impact it's making. We're excited to now make this available nationally."

In February this year, the company received 510(k) clearance from the US Food and Drug Administration for the Corplex P device.